Vnitr Lek 1994, 40(2):89-92

[Vasosan S--a cholestyramine in the treatment of hypercholesterolemia of various etiopathogenesis].

P Kolesár: III. interná klinika LF UK, Bratislava.

Cholestyramine was used for the first time in the treatment of hypercholesterolaemia by Tenneton in 1960 and it persist in the treatment to the present time. The authors had the opportunity to monitor under clinical conditions the hypolipidaemic action of cholestyramine - the preparation Vasosan (manufactured by AG Chemie, Germany) in the treatment of hypercholesterolaemia of different origin, and also when associated with hypertriacylglycerolaemia. The authors revealed that Vasosan S reduced significantly total cholesterol, LDL cholesterol and apoprotein B even after brief treatment (12 weeks) even when there is also hypertriacylglycerolaemia. The decrease of triacylglycerols is not significant, and the increase of HDL-cholesterol is not significant either. Vasosan does not affect the activity of AST, ALT, ALP and total bilirubin, it is well tolerated and causes few gastrointestinal side-effects which do not call for discontinuation of treatment.